Showing results (231-240 of 324) with videos related to
Sort By:
Pageof 33
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 10, 2026
β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell CarcinomaFrederico O Gleber-Netto, Deborah Silverman, Tongxin Xie, et al.Research Square|June 29, 2026
Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsMinying Zhang, Barbara Nassif Rausseo, Peixin Jiang, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccinationLuis M Vence, Chiyu Wang, Himabindu Pappu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanomaJohn F Toso, Vee J Gill, Patrick Hwu, et al.Cancer|December 3, 2016
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patientsDae Won Kim, Lauren E Haydu, Aron Y Joon, et al.Nature Communications|November 13, 2025
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitorsXuefeng Wang, Tingyi Li, Islam Eljilany, et al.Vaccines|January 22, 2024
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer PatientsChristopher W Dukes, Marine Potez, Jeffrey Lancet, et al.Cancer Cell|October 10, 2025
Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myelomaFrancesco Di Meo, Francesca Albano, Annamaria Cesarano, et al.Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.Pageof 33